Emma H Allott
Overview
Explore the profile of Emma H Allott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang L, Winter S, Olsson L, Hamilton A, Halliday S, Kirk E, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Sep;
33(12):1623-1632.
PMID: 39269980
Background: Vigorous physical activity has been associated with lower risk of fatal prostate cancer. However, mechanisms contributing to this relationship are not understood. Methods: We studied 117 men with prostate...
2.
Anderson C, Bensen J, Allott E, Basta P, Irwin D, Gerstel A, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Sep;
33(12):1556-1563.
PMID: 39240227
Background: Rapid growth in the number of US cancer survivors drives the need for ongoing research efforts to improve outcomes and experiences after cancer. In this study, we describe the...
3.
Kennedy S, Treacy O, Allott E, Eustace A, Lynam-Lennon N, Buckley N, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551698
Innovation in both detection and treatment of cancer is necessary for the constant improvement in therapeutic strategies, especially in patients with novel or resistant variants of cancer. Cancer mortality rates...
4.
Barr M, Baird A, Halliday S, Martin P, Allott E, Phelan J, et al.
Diagnostics (Basel)
. 2022 Oct;
12(10).
PMID: 36292049
The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR)...
5.
Craig E, Stopsack K, Evergren E, Penn L, Freedland S, Hamilton R, et al.
Prostate Cancer Prostatic Dis
. 2022 Jun;
25(4):641-649.
PMID: 35732821
Background: Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Statin use...
6.
Morgan R, Keeley D, Hazard E, Allott E, Wolf B, Savage S, et al.
Biology (Basel)
. 2022 May;
11(5).
PMID: 35625354
Prostate cancer is one of the most prevalent cancers worldwide, particularly affecting men living a western lifestyle and of African descent, suggesting risk factors that are genetic, environmental, and socioeconomic...
7.
Huang L, LaBonte M, Craig S, Finn S, Allott E
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326519
Prostate cancer is a major cause of disease for men globally. Inflammation, an established hallmark of cancer, is frequently observed in the prostate, though its contribution to prostate cancer risks...
8.
Allott E, Dean K, Robson T, Meaney C
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830906
Our understanding of cancer initiation, progression, and treatment is continually progressing through dedicated research achieved through laboratory investigation, clinical trials, and patient engagement. The importance and complexity of the microenvironment...
9.
Morgan R, da Silveira W, Kelly R, Overton I, Allott E, Hardiman G
Expert Rev Mol Diagn
. 2021 Oct;
21(12):1257-1271.
PMID: 34666586
Introduction: Advances in high-throughput sequencing have greatly advanced our understanding of long non-coding RNAs (lncRNAs) in a relatively short period of time. This has expanded our knowledge of cancer, particularly...
10.
Hayes B, Brady L, Sheill G, Baird A, Guinan E, Stanfill B, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572916
Interactions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts...